Proof of concept study to assess downstream effects of using combined intranasal fluticasone propionate plus azelastine nasal spray on asthmatic inflammation in patients with persistent asthma and allergic rhinitis.

Trial Profile

Proof of concept study to assess downstream effects of using combined intranasal fluticasone propionate plus azelastine nasal spray on asthmatic inflammation in patients with persistent asthma and allergic rhinitis.

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 22 Mar 2018

At a glance

  • Drugs Azelastine/fluticasone-propionate (Primary)
  • Indications Allergic rhinitis; Asthma
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Meda Pharmaceuticals
  • Most Recent Events

    • 19 Mar 2018 Planned End Date changed from 1 Dec 2018 to 1 Jun 2019.
    • 19 Mar 2018 Planned primary completion date changed from 1 Dec 2018 to 1 Jun 2019.
    • 19 Mar 2018 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top